To the full analysis
Integra LifeSciences Holdings stock: growth
IARTIntegra LifeSciences Holdings reported $1.64B in revenue for fiscal 2025, up 1.5% on the prior year, up 3.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
7.4%
per year from 2006 to 2025, per share 5.9%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 3.6% | 6.4% | 7.4% |
| Revenue per share | 5.6% | 6.0% | 5.9% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $419.3M | $29.41M | $60.18M |
| 2007 | $550.46M | $33.47M | $24.45M |
| 2008 | $654.6M | $34.93M | $59.19M |
| 2009 | $682.49M | $50.96M | $115.67M |
| 2010 | $732.07M | $65.67M | $68.43M |
| 2011 | $780.08M | $27.99M | $65.9M |
| 2012 | $830.87M | $41.2M | −$10.32M |
| 2013 | $836.21M | −$16.98M | $5.42M |
| 2014 | $928.31M | $34M | $37.07M |
| 2015 | $882.73M | −$3.52M | $61.07M |
| 2016 | $992.08M | $74.56M | $69.08M |
| 2017 | $1.19B | $64.74M | $71.04M |
| 2018 | $1.47B | $60.8M | $121.94M |
| 2019 | $1.52B | $50.2M | $96.9M |
| 2020 | $1.37B | $133.89M | $139.94M |
| 2021 | $1.54B | $169.08M | $264.35M |
| 2022 | $1.56B | $180.55M | $217.38M |
| 2023 | $1.54B | $67.74M | $73.09M |
| 2024 | $1.61B | −$6.94M | $24.96M |
| 2025 | $1.64B | −$516.47M | −$45.25M |
Revenue by segment
How Integra LifeSciences Holdings Corporation makes its money and how that has shifted. Names are as the company reports them.
- Codman Specialty Surgical73%
- Tissue Technologies27%
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| Codman Specialty Surgical | $1.14B | $1.2B | 73.4% |
| Tissue Technologies | $466.89M | $434.73M | 26.6% |
| Total revenue | $1.61B | $1.64B | 100% |
Revenue by region
Where Integra LifeSciences Holdings Corporation generates its revenue.
- United States74%
- Asia Pacific12%
- Europe10%
- Rest Of The World5%
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| United States | $1.19B | $1.2B | 73.7% |
| Asia Pacific | $176.61M | $189.25M | 11.6% |
| Europe | $158.5M | $162.67M | 9.9% |
| Rest Of The World | $82.74M | $78.58M | 4.8% |
| Total revenue | $1.61B | $1.64B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak since 13 Nov 2026, previously Neutral
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.